Crypto markets in 2025 were defined by ETF adoption, memecoins, and regulatory shifts. Our 2025 recap breaks down the key trends and what they signal for Bitcoin, altcoins, and DeFi going into 2026.
Coinbase shares rose 8% after Goldman Sachs upgraded the stock to “buy,” citing improving crypto market conditions and stronger trading volumes that could bolster the exchange’s revenue and long-term growth prospects.
Kevin O’Leary advises financial advisors to adopt a pragmatic crypto strategy, stressing risk controls, client education and disciplined allocation as digital assets integrate into mainstream portfolios.
Evening Bitcoin Market Report: concise review of today’s price action, news drivers and market sentiment – plus practical trading tips and long-term guidance for investors.
In a bold prediction, financial educator Robert Kiyosaki advises investors to “buy more, do not sell” Bitcoin, forecasting its surge to $250,000 this year. Kiyosaki emphasizes accumulating BTC in anticipation of significant future gains.
As Palo Alto Networks prepares for its upcoming stock split, investors are weighing the potential benefits. A stock split often increases liquidity and may attract more buyers, but analysts urge caution, emphasizing the need for a thorough evaluation of the company’s fundamentals before making any decisions.
Income investors should exercise caution with certain high-yield dividend stocks that may appear attractive but carry significant risks. This article examines two such stocks, highlighting potential pitfalls that could jeopardize your investment strategy.
Amidst the ever-changing landscape of the Bitcoin market, “Daily Bitcoin Market Briefs” emerges as a lifeline for investors seeking to navigate its turbulent waters. Harnessing advanced algorithms, these Briefs dissect market forces and price fluctuations with surgical precision. By identifying hidden trends and potential opportunities, they provide investors with critical insights to inform decision-making and optimize risk management. Tailored to meet the unique needs of investors, the Briefs empower them to stay ahead of the market’s unpredictable currents, unlocking the potential for maximum profitability in their Bitcoin investments.
Investors in search of a weight-loss play should look beyond underperforming Viking Therapeutics. Enterar Therapeutics (ENTX) is a promising contender with a differentiated approach. Their investigational drug, Entereg, targets a key hormone involved in appetite regulation, opening up a potentially lucrative market.
Enterar’s focus on neuroendocrine control sets it apart from traditional weight-loss therapies. With positive Phase 2b data and a Phase 3 trial underway, Enterar has significant catalysts ahead. Analysts are bullish, with a consensus price target of $25, representing a substantial upside.
While Viking Therapeutics has faced setbacks, Enterar Therapeutics presents a more compelling opportunity for investors seeking exposure to the burgeoning weight-loss market. Its unique mechanism of action, promising clinical data, and favorable analyst sentiment make it a stock to watch.